As the mutational burden has been associated with response to immune-modulatory drugs (18, 19), we explored if the expression of the identified immune signature CD2, CD3D, CD3E, CXCR6 was able to predict a better outcome in HNSCC and in CSCC with high mutational burden. Here, CD3E is linked to head and neck squamous cell carcinoma.